Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Medical Virology"
DOI: 10.1002/jmv.28210
Abstract: Nucleos(t)ide analogs (NAs) cannot completely suppress the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). This study aimed to identify the risk factors for HCC development in naïve CHB patients treated… read more here.
Keywords: hepatocellular carcinoma; year; nucleos ide; chronic hepatitis ... See more keywords
Comparison of Interferon-α-based therapy and nucleos(t)ide analogs in preventing adverse outcomes in patients with chronic hepatitis B.
Sign Up to like & getrecommendations! Published in 2021 at "Clinics and research in hepatology and gastroenterology"
DOI: 10.1016/j.clinre.2021.101758
Abstract: BACKGROUND Whether interferon (IFN)-α therapy is better than nucleos(t)ide analogs (NAs) in the prevention of adverse outcomes, including hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB) is still uncertain or controversial. This study… read more here.
Keywords: hcc; nucleos ide; outcomes patients; adverse outcomes ... See more keywords
Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of hepatology"
DOI: 10.1016/j.jhep.2017.09.018
Abstract: BACKGROUND & AIMS It is uncertain if nucleos(t)ide analogue (NA)-induced hepatitis B surface antigen (HBsAg) seroclearance is durable. We investigated the impact of hepatitis B surface antibody (anti-HBs) and duration of consolidation antiviral therapy on… read more here.
Keywords: hepatitis surface; seroclearance; nucleos ide; hbsag seroclearance ... See more keywords
The times they are a-changing - A refined proposal for finite HBV nucleos(t)ide analog therapy.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of hepatology"
DOI: 10.1016/j.jhep.2021.04.040
Abstract: Although discontinuation of nucleos(t)ide analogue (NA) treatment before HBsAg loss is part of all current hepatitis B virus (HBV) treatment guidelines for HBeAg-positive patients who achieved HBeAg seroconversion, a treatment endpoint known to be associated… read more here.
Keywords: nucleos ide; hbsag loss; treatment; hbv ... See more keywords
Biomarkers for predicting nucleos(t)ide analogs discontinuation and hepatitis B virus recurrence after drug withdrawal in chronic hepatitis B patients
Sign Up to like & getrecommendations! Published in 2022 at "Hepatology Research"
DOI: 10.1111/hepr.13749
Abstract: To summarize HBV‐related biomarkers predicting nucleos(t)ide analogs (NAs) discontinuation and hepatitis B virus (HBV) recurrence after drug withdrawal in chronic hepatitis B (CHB) patients, providing references for clinical medication, so as to manage CHB patients… read more here.
Keywords: biomarkers predicting; nucleos ide; predicting nucleos; hepatitis ... See more keywords
Outcome of nucleos(t)ide analog cessation in patients with treatment for prevention of or against hepatitis B virus reactivation
Sign Up to like & getrecommendations! Published in 2022 at "Hepatology Research"
DOI: 10.1111/hepr.13864
Abstract: We retrospectively investigated patients with administration of nucleos(t)ide analogs (NAs) for prevention of or against hepatitis B virus (HBV) reactivation, and their clinical outcomes after cessation of the NA. read more here.
Keywords: nucleos ide; prevention hepatitis; hepatitis virus;
Negative HBcAg in immunohistochemistry assay of liver biopsy is a predictive factor for the treatment of patients with nucleos(t)ide analogue therapy
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Cellular and Molecular Medicine"
DOI: 10.1111/jcmm.13444
Abstract: The hepatitis B core antigen (HBcAg) is an important target for antiviral response in chronic hepatitis B (CHB) patients. However, the correlation between HBcAg in the hepatocyte nucleus and nucleos(t)ide analogue (NA) therapeutic response is… read more here.
Keywords: week; nucleos ide; ide analogue; hbcag group ... See more keywords
Extrahepatic carcinogenicity of oral nucleos(t)ide analogues in chronic hepatitis B carriers: A 35,000‐Korean outcome study
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Viral Hepatitis"
DOI: 10.1111/jvh.13721
Abstract: Evidence on the carcinogenicity of oral nucleos(t)ide analogues (NAs) is inconclusive and lacks data on the effects by chemical structure of the NAs in patients with chronic hepatitis B (CHB). We aimed to provide definitive… read more here.
Keywords: nucleos ide; carcinogenicity oral; ide analogues; chronic hepatitis ... See more keywords
TDF Monotherapy Is Effective Regardless of Prior Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patients in China
Sign Up to like & getrecommendations! Published in 2017 at "BioMed Research International"
DOI: 10.1155/2017/2463197
Abstract: Background/Aims Many patients had to transfer to tenofovir disoproxil fumarate (TDF) if there is other nucleos(t)ide analogue (NA) resistance. We aimed to investigate antiviral effects of TDF monotherapy between NA-naive and NA-experienced chronic hepatitis B… read more here.
Keywords: nucleos ide; tdf monotherapy; ide analogue; dna ... See more keywords
Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleos(t)ide analog
Sign Up to like & getrecommendations! Published in 2022 at "PLoS ONE"
DOI: 10.1371/journal.pone.0262764
Abstract: Background To evaluate the long-term efficacy of switching of the nucleos(t)ide analog used for treatment from entecavir (ETV) to tenofovir alafenamide fumarate (TAF) in patients with chronic HBV infection. Methods A total of 103 patients… read more here.
Keywords: hbsag; nucleos ide; ide analog; hbv infection ... See more keywords
Safety Considerations for Withdrawal of Nucleos(t)ide Analogues in Patients with Chronic Hepatitis B: First, Do No Harm.
Sign Up to like & getrecommendations! Published in 2023 at "Clinical and molecular hepatology"
DOI: 10.3350/cmh.2022.0420
Abstract: Nucleos(t)ide analogues (NA) are widely used to treat hepatitis B virus (HBV) infection, but they cannot eradicate the virus and treatment duration can be lifelong if the endpoint is set at seroclearance of the hepatitis… read more here.
Keywords: safety; nucleos ide; ide analogues; hepatitis ... See more keywords